Skip to main content
PLOS One logoLink to PLOS One
. 2021 Oct 21;16(10):e0258697. doi: 10.1371/journal.pone.0258697

Evaluation of clinical outcomes of patients with mild symptoms of coronavirus disease 2019 (COVID-19) discharged from the emergency department

Hamidreza Morteza Bagi 1, Maryam Soleimanpour 2, Fariba Abdollahi 3, Hassan Soleimanpour 4,*
Editor: Edris Hasanpoor5
PMCID: PMC8530279  PMID: 34673806

Abstract

Introduction

This study was performed to determine the clinical outcomes of patients with mild symptoms of COVID-19 discharged from the emergency department.

Methods

The present descriptive-analytical cross-sectional study was performed on 400 patients discharged with a diagnosis of COVID-19 from the emergency departments of hospitals affiliated to Tabriz University of Medical Sciences in the time period of 21 March-21 June, 2020. The disease characteristics and demographic data were collected by phone calls during the first, third, and fourth weeks using a researcher-made questionnaire. Finally, the data were analyzed by univariate logistic regression and cross-tabulation using the IBM SPSS Statistics for Windows, version 20.

Results

In the first week of follow-up, 23(5.8%) patients died, of whom seven patients were female and 16 were male (mean age of death: 70.73±3.27). Out of 41 (10.3%) patients with underlying diseases, 7 (17.1%) died; but out of 359 (89.8%) cases with no history of disease only 16 (4.5%) died. The risk of death in subjects with a history of underlying diseases was 3.27 times higher than those without a history of disease (P = 0.02) (OR = 3.27, 95% CI, 1.20–8.87); and this risk was 1.41 times higher in patients with more family members (P = 0.04) (OR = 1.41, 95% CI, 1.01–1.97). Furthermore, 81 (20.3%) patients had spread the virus to others in their households and disregarded hygiene guidelines such as washing hands, keeping social distancing, and wearing face masks after discharge. In addition, family members of these patients were 16.37 times more likely to be infected than patients who followed the protocols (P ≤ 0.001) (OR = 16.37, 95% CI, 9.10–29.45).

Conclusion

Since our findings showed that mortality rate is high in the first week after patients’ referral to the emergency departments, the health status of infected people should be carefully monitored daily in this period.

Introduction

In December 2019, the Chinese government officially announced the outbreak of a novel coronavirus disease in Wuhan, which was then named as COVID-19 [1]. COVID-19 is the seventh coronavirus known to infect humans, and the third zoonotic virus after severe acute respiratory syndrome–related coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), which belong to the beta-coronavirus category [2]. The disease soon spread not only to different cities and regions of China, but also to other Asian countries. Then, the virus spread across Asia and became a global pandemic [3, 4]. On January 30, 2020, the World Health Organization (WHO) declared the pandemic a public health emergency of international concern (PHEIC). Most people experience mild to moderate respiratory illness and are treated without any specific medications. Older people and patients with underlying diseases such as cancer, cardiovascular, and respiratory diseases are more likely to develop severe levels of the disease [3]. The new coronavirus is more widespread in humans than previous coronaviruses, indicating the extremely high transmission rates of the virus [5, 6].

There is a growing concern about the disease for various reasons, including the unknown characteristics of the disease and ways to deal with it, high variety of symptoms, severe infection, long latency period, rapid and high transmission rates, as well as its negative impact on physical and mental health of the communities [7]. Due to the unavailability of antiviral drugs for COVID-19, the WHO recommended the following measurements to reduce the prevalence of infection: practicing personal hygiene and disinfection, early diagnosis and reporting, isolating infected patients, quarantines, proper and rational use of personal protective equipment, social distancing, and travel restrictions [8]. The best way to prevent and control the spread of this disease is to clearly identify the disease and its transmission routes [1]. Although the prevalence of COVID-19 has become a clinical threat to the general population and healthcare staff worldwide, the current knowledge about this new virus is still limited. However, an effective antiviral treatment along with vaccination programs are being evaluated and developed [3]. Currently, aggressive implementation of infection prevention and control (IPC) guidelines is the only option to prevent the spread of human-to-human transmission (HHT) of COVID-19 (3).

Given that COVID-19 pandemic has affected almost all important economic, political, social, and even military systems of all countries worldwide, it is important to discuss the consequences of this viral disease on the health of people at different levels of society [1]. Due to the pathogenesis of the virus and the high spread and mortality rates, COVID-19 can affect the health status of people at different levels of society, including patients, health care staff, families, children, students, and psychiatric patients in different ways. Therefore, in the current high-risk situation, it is necessary to identify the consequences of the disease in order to maintain the health of individuals with appropriate strategies and techniques [8]. Accordingly, this study was carried out to determine the clinical outcomes of patients with mild symptoms of COVID-19 discharged from the emergency departments of Tabriz University of Medical Sciences, Iran in 2020.

Materials and methods

The inclusion criteria of this descriptive-analytical cross-sectional study were: patients with mild COVID-19; patients discharged from the emergency department with the aim of home quarantine; and over 18 years of age. By mild COVID-19 symptoms we meant those patients in good general condition, oxygen level (SpO2) over 90%, non-intubated, and having mild fever and also who tested positive for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) assay of nasopharyngeal swabs. Patients’ unwillingness to participate were excluded from the study. This research was approved by the Research Ethics Committee of Tabriz University of Medical Sciences, Iran with No. IR.TBZMED.REC.1399.630 (14/09/2020). Informed consent was obtained from all participants by telephone at the beginning of the study after explaining the objectives and methods of the study. In addition, participants were assured that their information would remain confidential. The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to publish these case details.

Data collection tool was a researcher-made questionnaire. The first part of the questionnaire was related to demographic information of patients (age, sex, employment status, marital status, number of family members) and the second part was related to the characteristics of the disease (initial complaint, history of underlying disease, vital signs, the number of referrals to the emergency department, number of infected people in the family, general condition and type of treatment on days 3, 7, and 30, hygiene compliance, reasons for hygiene non-compliance). To determine the reliability of the researcher-made questionnaire, the test-retest method was used on 30 patients; the questions were re-asked by telephone after two weeks, the reliability of which was 0.94. Content validity was used to determine the validity of the questionnaire during the study process. The questionnaire, that had been prepared according to the objectives of the research and review of related literature, was approved by the supervisor. Then, the questionnaire was given to 10 faculty members at Tabriz University of Medical Sciences, and the content validity was approved (S1 and S2 Files). All patients with mild COVID-19 symptoms discharged from the emergency departments of hospitals affiliated to Tabriz University of Medical Sciences in the time period of 21 March-21 June, 2020 were included in the study; the patients were under home quarantine. The sampling method was cluster sampling so that Imam Reza Hospital, Teaching hospital in Tabriz city, with 860 beds and Sina Hospital, Teaching hospital in Tabriz city, with 279 beds as the referral COVID-19 centers, were considered as main clusters. Using patient records, the proportion of patients from each cluster in proportion to the size of that cluster was done randomly. According to Morgan’s table, 243 patients from 700 patients referred to the emergency department of Imam Reza Hospital and 152 patients from 300 patients referred to the emergency department of Sina Hospital were selected. The information recorded in the patients’ files and the data obtained during the follow-up stage by phone calls were used in the study. Then, all patients were followed up by telephone during the first, third, and fourth weeks. Using the IBM SPSS Statistics for Windows, version 20 (IBM Corp., Armonk, N.Y., USA), data were analyzed using descriptive statistical methods (tables, graphs, mean, and standard deviation) and analytical statistics (univariate logistics and cross-tabulation).

Results

In this study, out of 400 patients discharged from the emergency departments of Imam Reza and Sina hospitals in Tabriz, 235 (58.8%) were male and 165 (41.3%) were female with a mean (standard deviation) age of 49.40±17.02 years. Married patients (354 (88.5%)), housewives (122 (30.5%)), pensioners (70 (17.5%)), and freelancers (69 (17.3%)) were the most prevalent groups, respectively. In addition, 130 (32.5%) patients had a family size of four, 108 (27%) had a family size of three, and 63 (15.8%) had a family size of five (Table 1). In addition, 41 (11.2%) patients had a history of underlying diseases, including heart, lung, and kidney diseases (Table 1). The results showed that the mean diastolic blood pressure of the patients was 77.79±8.60, the mean systolic blood pressure was 125.33±13.57, the mean heart rate was 85.39±13.35, and the mean respiratory rate was 20.40±3.91 (Table 2). In addition, the mean percentage of oxygen saturation in arterial blood was 94.91±2.09. The minimum percentage of oxygen saturation in patients with mild symptoms ranged between 91 and 99. Also, the mean temperature of patients was 37.62 ±0.65 (range: 37 to 39), indicating the presence of fever in patients. Furthermore, the most common and initial complaints of patients were cold symptoms such as fever, myalgia, and cough. Among the participants, 69 (17.3%) patients had referred to the emergency department for two times and 25 (6.3%) patients for three times.

Table 1. Characteristics of the 400 included patients.

variable percent Frequency
Sex Male 58.8 235
Female 41.3 165
marital Married 88.5 354
Single 11.5 46
job Retired 17.5 70
Housewife 30.5 122
Self-employed 17.3 69
Unemployed 2.3 9
Manual worker 7.2 29
Judge 0.3 1
Students 2.5 10
Factory worker 3.8 15
Employee 11.8 47
Carpet weaver 1.5 6
Doctor 2.3 9
Nurse 1.8 7
Student 1.5 6
The Number of family members 3 27 108
4 32.5 130
5 15.8 63
Past medical history of patients/Underling disease NO 89.9 359
Heart disease 7.5 30
Kidney disease 1 4
Pulmonary disease 0.8 3
Fatty liver 0.5 2
Compromised immune systems 0.5 2
Frequency of Prescribed Medications No medicine 12.5 50
Chloroquine, theophylline 2.0 8
Chloroquine 49.3 197
Chloroquine, azithromycin 3.5 14
Azithromycin 1.5 6
Aminophylline, chloroquine 11.8 47
Chloroquine, aminophylline and azithromycin 19.5 78
Chief compliment of patients discharged from ED Common cold 12 48
Weakness and Dizziness 1.8 7
Chest pain 4 16
Dyspnea 6.8 27
Myalgia 10.3 41
Cough 12 48
Fever 11.3 45
Diarrhea and Vomiting 6.3 25
Sweating 2.8 11
Headache 3.8 15
Common cold and Chest pain 4.3 17
No symptom 3.5 14
Myalgia and Dizziness 1 4
Dyspnea and Cough 2.8 11
Cough and Myalgia 7 28
Fever and Myalgia 1.5 6
Fever and Cough 4.3 17
Vomiting and Fever 1.3 5
Cough, Anorexia and Myalgia 2.5 10
Fever, Cough and Myalgia 1.3 5
Patients need to revisit in the ED Second Time 17.3 69
Third Time 6.36 25
No 76.5 306

Table 2. Patients’ vital signs.

N Minimum Maximum Mean Std. Deviation
SBP 400 100.00 166.00 125.3300 13.57929
DBP 400 51.00 93.00 77.7950 8.60891
HR 400 58.00 109.00 85.3900 13.35398
RR 400 12.00 30.00 20.4075 3.91468
Sat 400 91.00 99.00 94.9150 2.09374
GCS 400 15.00 15.00 15.0000 .00000
BT 400 37.00 39.00 37.6288 .65008
Total 400

Medications used in the patients

The results showed that chloroquine was prescribed to most of the patients (49.3%) at the time of discharge from the emergency departments. The frequency of medications prescribed to patients is given in Table 1.

Chief compliment of patients and so patients need to revisit

In Table 1 chief compliment of patients discharged from ED and so patients need to revisit in the ED has been shown.

Disease outcomes

In this study, after one week of follow-up, 240 (60%) patients reported their general condition as good and 137 (34.3%) as bad after being discharged from the emergency departments. Unfortunately, 23 (5.8%) patients died in the first week of follow-up, of whom seven were female and 16 were male. Also, the mean age of death was 70.73±3.27 years (Fig 1).

Fig 1. The frequency of mortality rate.

Fig 1

Regarding the association between mortality rate and underlying diseases, the results showed that out of 41 (10.3%) patients with underlying diseases, 7 (17.1%) died; however, there were only 16 (4.5%) death cases out of 359 (89.8%) patients with no history of disease. In the third week, 324 (81%) patients were in good general condition and 53 (13.3%) patients were in bad general condition. Follow-up results on day 30 after discharge showed that 94.3% of patients were in good general condition. Evaluating the relationship between mortality rate with underlying diseases and the number of family members showed that the risk of death in subjects with a history of underlying diseases was 3.27 times higher than those without a history of disease (P = 0.02) (OR = 3.27, 95% CI, 1.20–8.87); and this risk was 1.41 times higher in patients with more family members (P = 0.04) (OR = 1.41, 95% CI, 1.01–1.97).

Within-household transmission of COVID-19 and hygiene compliance rate

Regarding the within-household transmission of COVID-19, our results showed that 81 (20.3%) patients had spread the virus to others in their households and disregarded hygiene guidelines such as washing hands, keeping social distancing, and wearing face masks after discharge. Furthermore, two main reasons were identified for non-compliance of hygiene guidelines as follows: small size of the houses (56%) and economic reasons (49%). In addition, family members of these patients were 16.37 times more likely to be infected than patients who followed the protocols (P ≤ 0.001) (OR = 16.37, 95% CI, 9.10–29.45).

Discussion

The COVID-19 virus is mainly transmitted through saliva droplets or nasal discharge when coughing or sneezing [3]. In this study, risk of death in subjects with a history of underlying diseases was higher than others and so 30 (7.5%) of patients had heart disease, 4 (1%) had kidney disease, 3 (0.8%) had lung disease, and 2 (0.5%) had immune system disease. In addition, out of 23 patients who died, seven cases had underlying diseases. Therefore, it can be concluded that patients with underlying diseases such as cancer, cardiovascular, or respiratory disease are more likely to develop severe levels of the disease. Our study showed that 81 (20.3%) patients not only did not follow the health protocols after discharge, but also transmitted the disease to other family members, indicating a significant relationship between the spread of the disease and hygiene non-compliance. In this regard, family members of these patients were 16.37 times more likely to be infected than patients who followed the protocols (P ≤ 0.001) (OR = 16.37, 95% CI, 9.10–29.45). This finding confirms that the COVID-19 is more widespread in humans than previous coronaviruses, indicating its extremely high transmission rate [7]. Studies have shown that the mortality rate of COVID-19 is much lower (4.3%) than other coronaviruses, such as SARS (9.6%) MERS (35.2%), HIV, and Ebola [6, 912]. In this study, out of 400 patients, 23 (5.8%) died, which demonstrates a high mortality rate. However, a growing concern has been raised about this disease due to various reasons, including the unknown nature of the disease and ways to deal with it, high variety of symptoms, severe infection, long latency period, and high transmission rate [7]. Studies show that quarantines are used less frequently in large epidemics when people do not support them [7]. Large-scale quarantines can give the health care system a chance to be more resilient to large numbers of patients by delaying the epidemic peak [8]. In our study, the results of examining the relationship between mortality rate and the household size showed that with increasing the number of family members, the risk of death increased by 1.41 times (P = 0.04) (OR = 1.41, 95% CI, 1.01–1.97). This indicates the inability to stay in quarantine and hygiene non-compliance for various reasons such as economic reasons, small size of houses, and lack of essential equipment. Wang et al. showed that the number of COVID-19 cases in China increased by 31.4 times during 10–24 January, 2020; in addition, on February 23, 2020, the number of infected people in China was 1,879 times higher than January 10, 2020. They estimated the mortality rate as 2.84% based on the number of patients. The researchers also found that the male-to-female mortality rate was 3.25 to 1, the median age of death was 75 years, and the median time from initial symptoms to death was 14 days [13]. In the present study, the mean age of death was 70.7 years, and most of them were males who died seven days after referring to the emergency departments. Saad et al. reported that the virus could cause severe infections requiring intensive care; concomitant infections and low albumin levels could predict severe infection, whereas age 65 was the only predictor of increased mortality [14]. Liu et al. [15] evaluated the effectiveness of hospitalization after two weeks and reported that 11 (14.1%) patients developed severe levels of the disease; meanwhile, 67 (85.9%) patients were treated effectively. Moreover, patients in the severe group were significantly older than patients in the treated group. Several risk factors contributing to the progression of COVID-19 were identified, including age, maximum body temperature at admission, respiratory failure, albumin level, and C-reactive protein (CRP). In this study, hygiene non-compliance, a history of underlying diseases, and a larger family size increased the risk of disease progression. These results can be used in most cases for better management of COVID-19 pandemic. Shahyad et al. reported that not only this contagious disease has raised concerns about public physical health, but also it has caused a number of psychological disorders. In these circumstances, maintaining the mental health of communities is essential because people in different social levels may experience stressful stimuli during the pandemic. Therefore, in the current high-risk situation, identifying people prone to psychological disorders at different social levels is necessary to maintain the mental health of individuals with appropriate psychological strategies and techniques [16]. In the research by Ghonoodi et al., the major barriers for the implementation of quarantine were the lack of knowledge and awareness among communities and financial problems; meanwhile, the main facilitating factor was increasing the knowledge and awareness about quarantine among the communities. For better implementation of quarantines, socio-economic supportive incentives and strengthening of information and educational programs are suggested [17]. In our study, out of 400 patients, 81 individuals did not stay at home due to economic reasons and small house size, which is consistent with the results of Ghonoodi et al [17]. Hagh-Ghadam et al. investigated the psychological consequences and interventions during the COVID-19 pandemic in Iran and reported that psychological disorders such as post-traumatic stress disorder (PTSD), depression, anxiety, stress, sleep disorders, and anger were significantly increased in the health care staff and other people involved with COVID-19. Stressors included health anxiety, conspiracy theories, prolonged quarantine, fear of disease transmission, frustration, fatigue, lack of protective equipment, insufficient information, financial loss, rumors, negative beliefs about vaccination, and stigma. In addition, their findings showed that online cognitive-behavioral therapy approach is effective at the time of COVID-19 outbreak. Their review study demonstrated a decrease in mental health of people, especially medical staff. In addition, the researchers recommended that it is necessary to provide fast, continuous, and timely psychological interventions, especially online services. Finally, they suggested that providing online psychological services is better than face-to-face ones [18]. Tavakoli et al. reported the incubation period of COVID-19 as 2–10 days. Overall, the fatality rate of COVID-19 was 4.3%, and the results indicated that the mortality was higher in elderly individuals and patients with chronic conditions, including those with coronary artery disease, diabetes, chronic pulmonary disease, and hypertension. In addition, the mortality rate in healthy subjects was less than 1%, which is consistent with the results of the present study [6]. There was a study in 2020 which had been conducted by Knight et al. It was carried out on 106 patients with mild COVID-19 who were also treated on an out-patient manner. All patients underwent follow up until their PCR tests were negative twice. The average age mean for patients was 51 years and half of them were male. It is about 36.5% of patients had at least one risk factor with asthma (16%) and diabetes (10%) which were the most common types. Most patients (98.1%) had symptoms such as cough (80.4%), fatigue (67.6%), fever (66.0%), headache (49.0%), and ageusia (46.9%). Nine number of patients (8.5%) were admitted in the emergency room and 5 patients (4.7%) were hospitalized. And none of them died. Asthma and immune-compromised were two risk factors with poor prognosis [19]. In our study, number of male patients was 58.8%, 17.5% were retired, 30.5% were housewives, 2.8% were physicians, and 1.8% were nurses. The majority of patients received chloroquine and azithromycin (87.5%) and the rest (12.5%) did not receive any medication. Among 400 discharged patients from the emergency room of Imam Reza general hospital and Sina hospital in Tabriz, 235 numbers were male and 354 were married. The majority of patients had a family of four members. In the first week of patients leave, 240 patients were reported well, 137 patients in bad condition and 23 deaths were reported. After 30 days, 377 patients were reported with good general condition. Results showed that 69 patients (17.25%) referred to the emergency department for the second time and 25 patients (6.25%) for the third time. At all, 23.5% of patients referred to the emergency. After discharge, 81 number of patients were transferred disease to their families. There was a meaningful correlation between disease transmission and the number of family members. The most common symptoms were fever, myalgia and cough. It was about 11.2% of patients had underlying kidney, lung, and heart diseases. In our study, 5.8% of patients (23 numbers) died in the first week with an average age of 70.73 ± 3.27. Findings of the present study showed that 20.3% of patients did not follow hygienic protocols such as hand washing, social distancing and mask usage after discharge. Also, using Chi-square tests, the results demonstrated that there is a statistically significant relationship between mortality and non-following of health protocol (p = 0.000). In another study conducted by Halalau et al. on 821 patients with an average age of 49.3 years and 46.8% male gender, in 8 hospitals in 2020 year, patients were followed-up at least 12 days after the visit which it included of subsequent ED visit, admission status, and mortality. Cough was the most common symptom of 78.2% with an average of three days long. Other symptoms were 62.1% fever, 35.1% rhinorrhea or nasal congestion and 31.2% dyspnea, respectively. ACEI / ARBs consumption were reported in 28.7% of patients and 34% of patients had a history of diabetes. It was an interesting point that 19.2% of patients were referred to the emergency in which 54.4% of them were admitted. Most of admitted patients were older than discharged patients (mean age 54.4 vs 48.7 years, p = 0.002). Also, hospitalized patients had a higher percentage of blood pressure than those discharged (p<0.001). In addition, the hospitalized patients had a higher BMI than the discharged ones (p = 0.004). Diabetes, pre-diabetes, COPD and OSA increased also in hospitalized in the mentioned individuals rather than out-patients (p < 0.001) [20]. Overall mortality among above mentioned out-patients was 1.3%. Finally, it is hopeful to announce that the majority of patients with COVID-19 recovered without receiving any specific medication, and only sixth of patients developed respiratory problems [21]. And the number of patients who needed ICU was 5% [22]. However, our study was multicenter with relatively modest sample size but larger and further multicenter studies are required to confirm our results.

Conclusion

Our results confirmed that COVID-19 is more prevalent in males than females, and the disease has a very high transmission rate. There was a significant association between the history of underlying diseases and the higher number of family members with the mortality rate. Moreover, a significant relationship was seen between the number of family members and transmission rate of the disease. Since our findings showed that mortality rate is high in the first week after patients’ referral to the emergency departments, the health status of infected people should be carefully monitored daily in this period.

Supporting information

S1 File. Original version (Persian) of relevant parts of the questionnaires used in the study.

(DOC)

S2 File. Questionnaire.

English translation and so original version (Persian) of relevant parts of the questionnaires used in the study.

(DOC)

Acknowledgments

This study has been extracted from a M.D dissertation at Tabriz University of Medical Sciences, Iran. The authors wish to thank the Clinical Research Development Unit, Imam Reza General Hospital, Tabriz University of Medical Sciences, Tabriz, Iran and so the Clinical Research Development Unit of Sina Educational, Research and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran for their sincere collaboration.

Abbreviations

COPD

Chronic obstructive pulmonary disease

ED

Emergency department

OSA

Obstructive sleep apnea

Data Availability

All relevant data are within the paper and its Supporting information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): a perspective from China. Radiology. 2020:200490. doi: 10.1148/radiol.2020200490 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.da Costa VG, Moreli ML, Saivish MV. The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century. Archives of Virology. 2020:1–10. doi: 10.1007/s00705-020-04628-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Organization WH. Health Topics. Coronavírus. Coronavirus: symptoms World Health Organization, 2020a Disponível em: https://wwwwhoint/healthtopics/coronavirus#tab=tab_3Acessoem. 2020;7.
  • 4.MacKenzie D. Covid-19 goes global. New Sci. 2020. Feb 29; 245(3271):7. doi: 10.1016/S0262-4079(20)30424-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Akande OW, Akande TM. COVID-19 pandemic: A global health burden. Nigerian Postgraduate Medical Journal. 2020;27(3):147. doi: 10.4103/npmj.npmj_157_20 [DOI] [PubMed] [Google Scholar]
  • 6.Tavakoli A, Vahdat K, Keshavarz M. Novel coronavirus disease 2019 (COVID-19): an emerging infectious disease in the 21st century. ISMJ. 2020; 22(6):432–50. [Google Scholar]
  • 7.Gao J, Zheng P, Jia Y, Chen H, Mao Y, Chen S, et al. Mental health problems and social media exposure during COVID-19 outbreak. Plos one. 2020; 15(4):e0231924. doi: 10.1371/journal.pone.0231924 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Wilder-Smith A, Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak. Journal of travel medicine. 2020;27(2):taaa020. doi: 10.1093/jtm/taaa020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Novel 2019 Coronavirus Genome. virological.org. (Accessed January 19, 2020, at http://virological.org/t/novel-2019-coronavirus-genome/319)
  • 10.Xu J, Zhao S, Teng T, et al. Systematic Comparison Of Two Animal-To-Human Transmitted Human Coronaviruses: SARS-Cov2 And SARS-Cov. Viruses 2020; 12(2): e244 doi: 10.3390/v12020244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Al Awaidy ST, Khamis F. Middle East Respiratory Syndrome Coronavirus(MERS-Cov) In Oman: Current Situation And Going Forward. Oman Med J 2019; 34(3): 181–3. doi: 10.5001/omj.2019.36 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, et al. Transmission dynamics and control of severe acute respiratory syndrome. Science. 2003; 300(5627):1966–70. doi: 10.1126/science.1086616 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. Journal of medical virology. 2020;92(4):441–7. doi: 10.1002/jmv.25689 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. International Journal of Infectious Diseases. 2014;29:301–6. doi: 10.1016/j.ijid.2014.09.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Liu W, Tao Z-W, Wang L, Yuan M-L, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese medical journal. 2020. doi: 10.1097/CM9.0000000000000775 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Shahyad S, Mohammadi MT. Psychological impacts of COVID-19 outbreak on mental health status of society individuals: A narrative review. Journal of Military Medicine. 2020; 22(2). [Google Scholar]
  • 17.Ghonoodi F, Mohammadnejad E, Ehsani S R, Salehi Z. Quarantine Barriers and Facilitators in COVID-19 pandemic: Short Communication. MCS. 2020; 7 (1): 73–77 [Google Scholar]
  • 18.Shahed hagh ghadam H, Fathi Ashtiani A, Rahnejat A M, Ahmadi Tahour Soltani M, Taghva A, Ebrahimi M R, et al. Psychological Consequences and Interventions during the COVID-19 Pandemic: Narrative Review. J Mar Med. 2020; 2 (1): 1–11. URL: http://jmarmed.ir/article-1-74-en.html [Google Scholar]
  • 19.Knight D, Downes K, Munipalli B, Halkar MG, Logvinov II, Speicher LL, et al. Symptoms and Clinical Outcomes of Coronavirus Disease 2019 in the Outpatient Setting. SN Compr Clin Med. 2021. Jan 14:1–8. doi: 10.1007/s42399-021-00746-1 Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Halalau A, Odish F, Imam Z, Sharrak A, Brickner E, Lee PB, et al. Epidemiology, Clinical Characteristics, and Outcomes of a Large Cohort of COVID-19 Outpatients in Michigan. Int J Gen Med. 2021. Apr 28;14:1555–1563. doi: 10.2147/IJGM.S305295 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Shahsavarinia K, Ghojazadeh M, Ghabousian A, Hatefnia F, Soleimanpour M, et al. An Umbrella Review of Clinical Efficacy and Adverse Cardiac Events Associated with Hydroxychloroquine or Chloroquine with or Without Azithromycin in Patients with COVID-19. Anesth Pain Med. 2021;11(4):e115827. doi: 10.5812/aapm.115827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. JAMA. 2020. doi: 10.1001/jama.2020.3633 [PubMed: ]. [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Edris Hasanpoor

23 Aug 2021

PONE-D-21-20101

Evaluation of Clinical Outcomes of Patients with Mild Symptoms of Coronavirus Disease 2019 (COVID-19) Discharged from the Emergency Departments

PLOS ONE

Dear Dr. Soleimanpour,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 07 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Edris Hasanpoor

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that your paper includes detailed descriptions of individual patients/participants. As per the PLOS ONE policy (http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research) on papers that include identifying, or potentially identifying, information, the individual(s) or parent(s)/guardian(s) must be informed of the terms of the PLOS open-access (CC-BY) license and provide specific permission for publication of these details under the terms of this license. Please download the Consent Form for Publication in a PLOS Journal (http://journals.plos.org/plosone/s/file?id=8ce6/plos-consent-form-english.pdf). The signed consent form should not be submitted with the manuscript, but should be securely filed in the individual's case notes. Please amend the methods section and ethics statement of the manuscript to explicitly state that the patient/participant has provided consent for publication: “The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to publish these case details

3. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information.

4. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

5. Please ensure that you refer to Figure 1 in your text as, if accepted, production will need this reference to link the reader to the figure.

6. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 1 in your text; if accepted, production will need this reference to link the reader to the Table.

7. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Associate editor

Thanks to the authors. I reviewed the article. It is valuable research in the pandemic era. The title, introduction, methodology, and conclusion are appropriate. There is no plagiarism in it. The writing is appropriate and completely understandable. Moreover, recommendations are consistent with the finding, and referencing and citations were correct and so English writing was acceptable. The article needs minor revision and can be acceptable for publication. My comments are as follows:

1- The authors do not discuss the specifics of the hospital involved in the study.

2- Please mention the weak and strong points of your study

Reviewer #2: 1-Is there any information regarding the severity scores like APACHE or SAPS in the study population?

2-There should be a table showing demographic characteristics of the patients in the study.

3-is there any information about the duration of ED stay, method of ventilation, prescribed drugs, antiviral drugs, ...?

4-What was the criteria used for mild category of COVID-19 in this study?

5-What was the criteria for discharge of patients from ED?

6-it is better to show the any information about ED revisits, inpatient admissions, ICU admissions after discharge from hopital.

7-How did the authors delete the effect of confounding factors from the study outcome?

8-Discussion should be improved and revised based on the study results and comparison with previous ones.

9-What is the new finding of this study compared to previous ones the this field?

10-Is there any data regarding economic situation of patients,as previous studies showed an important economic consequence of the disease at an early post-hospital phase.

11-What was the limitation of the study?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Ata Mahmoodpoor

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Oct 21;16(10):e0258697. doi: 10.1371/journal.pone.0258697.r002

Author response to Decision Letter 0


13 Sep 2021

Dear Respected Editor and reviewers

Many thanks for your comprehensive comments regarding our article. Herewith, we revised our article based on your advice in the best manner as follows:

Reviewer #1:

Dear Reviewer 1

I appreciate you for reviewing our manuscript so meticulously and mentioning very important comments. Below you could find our reply to your comments.

Q1: The authors do not discuss the specifics of the hospital involved in the study.

� Reply: Based on your comment, we explained the specifics of the hospitals involved in the study in the Method section.

Q2: Please mention the weak and strong points of your study

� Reply: Based on your comment, we explained the weak and strength of study in end of discussion section.

Reviewer #2:

Dear Reviewer 2

I appreciate you for reviewing our manuscript so meticulously and mentioning very important comments. Below you could find our reply to your comments.

Q 1-Is there any information regarding the severity scores like APACHE or SAPS in the study population?

� Reply: Thank you so much for reviewing our manuscript meticulously. Since our included patients were outpatient’s patients we couldn’t collected data for calculating the APACHE or SAPS due to cost problem. Furthermore, based on the literature and experts’ opinion the mentioned predictor scores is not suitable for COVID-19 patients.

Q2- There should be a table showing demographic characteristics of the patients in the study.

� Reply: I really appreciate you for your comprehensive comments. We provided 3 tables (1, 2 and 5) regarding your nice advice.

Q3-is there any information about the duration of ED stay, method of ventilation, prescribed drugs, antiviral drugs...?

� Reply: We studied discharged outpatient patients from ED no need to ventilation or ED stay. The prescribed drug is mentioned in Table 4.

Q4-What was the criteria used for mild category of COVID-19 in this study?

� Reply: We meant those patients in good general condition, oxygen level (SpO2) over 90%, non-intubated, and having mild fever and also who tested positive for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) assay of nasopharyngeal swabs.

Q5-What was the criteria for discharge of patients from ED?

� Reply: We discharged patients in good general condition, oxygen level (SpO2) over 90%, non-intubated, and having mild fever and also who tested positive for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) assay of nasopharyngeal swabs.

6-it is better to show the any information about ED revisits, inpatient admissions, ICU admissions after discharge from hospital.

� Reply: Thank you for your valuable comment. The required data has been show in the Table 6 and figure 1

7-How did the authors delete the effect of confounding factors from the study outcome?

Reply- : We meant those patients in good general condition, oxygen level (SpO2) over 90%, non-intubated, and having mild fever and also who tested positive for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) assay of nasopharyngeal swabs.

8-Discussion should be improved and revised based on the study results and comparison with previous ones.

Reply- Many thanks for your attention. We did comprehensive review and improved the discussion section by the similar studies.

Q9-What is the new finding of this study compared to previous ones the this field?

Reply- We discussed the mortality, Household Transmission of COVID-19 and Hygiene Compliance Rate and so revisit of the Mild covid-19 outpatients discharged from ED.

10-Is there any data regarding economic situation of patients,as previous studies showed an important economic consequence of the disease at an early post-hospital phase.

Reply- In Table 1 the patients’ job is explained.

11-What was the limitation of the study?

Reply- Based on your comment, we explained the weak and strength of study in end of discussion section.

Attachment

Submitted filename: Dear Respected Editor and reviewers.doc

Decision Letter 1

Edris Hasanpoor

4 Oct 2021

Evaluation of Clinical Outcomes of Patients with Mild Symptoms of Coronavirus Disease 2019 (COVID-19) Discharged from the Emergency Departments

PONE-D-21-20101R1

Dear Dr. Soleimanpour

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Edris Hasanpoor

Academic Editor

PLOS ONE

Acceptance letter

Edris Hasanpoor

13 Oct 2021

PONE-D-21-20101R1

Evaluation of Clinical Outcomes of Patients with Mild Symptoms of Coronavirus Disease 2019 (COVID-19) Discharged from the Emergency Department

Dear Dr. Soleimanpour:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Edris Hasanpoor

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Original version (Persian) of relevant parts of the questionnaires used in the study.

    (DOC)

    S2 File. Questionnaire.

    English translation and so original version (Persian) of relevant parts of the questionnaires used in the study.

    (DOC)

    Attachment

    Submitted filename: Dear Respected Editor and reviewers.doc

    Data Availability Statement

    All relevant data are within the paper and its Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES